Composition
PONAXEN 15 Tablet: Each film-coated tablet contains Ponatinib Hydrochloride INN equivalent to Ponatinib 15 mg.
PONAXEN 45 Tablet: Each film-coated tablet contains Ponatinib Hydrochloride INN equivalent to Ponatinib 45 mg.
How To Use Ponaxen 15 mg
Take ponaxen ponatinib 15 only as directed by your physician. The standard dose is one 15 mg tablet taken once a day; swallow the tablet whole with water.
1. Dosage: The recommended dosage is one ponaxen 15 Mg tablet taken once a day or as directed by your physician.
2. How to take: Swallow the tablet whole with a glass of water. Do not split, chew, or break it.
3. Food: With or without food or without food at the same time every day for consistency
4. Missed Dose:
- Take ponatinib tablets as soon as remembered.
- If it’s almost time for the next dose, skip the missed dose.
- Do not take a double dose.
5. Avoid: Grapefruit and its juice; they can alter some medicines’ absorption.
6. Monitoring: Blood tests and liver function checks are necessary during ponatinib tablets treatment.
Always check with your doctor for adjustments in the dosage or management of side effects.
Indications of Ponaxen 15 Mg
Ponaxen is a potent tyrosine kinase inhibitor developed to overcome resistance and intolerance poses in patients with particular leukemias. This is used for adult patients for chronic myeloid leukemia (CML) in any phase, chronic, accelerated or blast phases, who are resistant to either dasatinib or nilotinib. It is also an option for patients intolerant of these therapies and for whom imatinib is not a clinically suitable alternative. This is especially significant for T315I mutant patients as this mutation is an indicator of resistance and limits the effectiveness of other tyrosine kinase inhibitors.
In Philadelphia chromosome-positive acute lymphoblastic leukemia treatment (Ph ALL) conditions for adults most resistant to dasatinib or intolerant of this medication, imatinib is not a candidate for subsequent therapy, ponatinib is recommended. Moreover, it is also a crucial line of therapy for patients with T315I mutation, which confers extreme drug resistance.
Through its novel mechanism of action, Ponaxen offers a valuable new therapeutic option to patients who have exhausted the available options due to pharmacoresistance or intolerance, bringing new hope in the treatment of CML and (Ph ALL).
DOSAGE AND ADMINISTRATION
ponaxen ponatinib 15 Therapy should be started by a physician expert in the diagnosis and treatment of patients with leukemia. Haemat-ologic support, such as platelet transfusion and hematopoietic growth factors, can be administered during treatment if clinically indicated.
Patients should undergo cardiovascular evaluation (history and physical examination) before the initiation of ponatinib therapy, and cardiovascular risk factors should be aggressively managed. During ponatinib treatment, cardiovascular status should be continually monitored and medical and supportive therapy for cardiovascular risk factors should be optimized.
RECOMMENDED DOSAGE
Ponatinib is dosed once daily, with a standard starting dose of 45 mg. Treatment should be continued until evidence of disease progression or unacceptable toxicity. If full haematologic response has not been achieved by 3 months (90 days), ponatinib discontinuation should be considered.
The risk of arterial occlusive events is probably dose related.
Patients with CP-CML who have achieved a major cytogenetic response on ponatinib should be considered for dose reduction to 15 mg, with assessment of individual patient cardiovascular risk, ponatinib side effects, time to cytogenetic response and BCR-ABL transcript levels. If dose reduction is performed, response should be closely monitored.
DOSAGE MODIFICATIONS
Dose modifications or discontinuation of dosing should be applied for the management of hematological and non-hematological toxicities. Where there is a serious adverse reaction treatment should be discontinued
For patients, when clinically appropriate, whose adverse reactions have been resolved or attenuated in severity, ponatinib may be reinstated and upward dose escalation back to the daily dose used before the adverse reaction may be considered.
Dose adjustments for neutropenia [absolute neutrophil count (ANC) 75 x 10%/L
Recurrence at 45 mg:
Ponatinib would be held and restarted at 30 mg after returning to ANC > 1.5 x 10% L; platelet > 75 x 10% /L
Recurrence at 15 mg:
Ponatinib should be withheld and resumed at 15 mg after recovery to ANC > 1.5 x 10%/L and platelet > 75 x 109/L
FAQ
1. What is Ponaxen 15 mg used for?
Ponaxen 15 mg (Ponatinib) is indicated for the treatment of patients with resistant or intolerant CML/Ph+ ALL.
2. How should I take Ponaxen 15 mg?
Swallow one tablet (15 mg) whole with water once daily. It can be taken with or without food, but it should be taken at the same time every day.
3. What should I do if I miss a dose?
If you forget to take a dose, do so as soon as you remember. But if it is close to the time for the next dose, skip the missed dose and just continue as usual. Do not double the dose.
4. Are there any foods or drinks I should avoid?
Yes, steer clear of grapefruit and grapefruit juice, which can affect the way the drug is absorbed and its effectiveness.
5. What are the common side effects of Ponaxen 15 mg?
Serious side effects can include high blood pressure, skin rash, fatigue, abdominal pain, nausea, headache and joint pain. This requires regular monitoring to manage side effects.
6. Can I stop taking Ponaxen 15 mg if I feel better?
Do not take Ponaxen for longer than prescribed and do not stop taking Ponaxen even if you feel better at some point without consulting your doctor. Such a snap decision could give tumours the upper hand. Always consult your doctor before making any health decisions.
Disclaimer
The information provided is intended for educational and informational purposes only and should not be regarded as medical advice or a replacement for consulting with a licensed healthcare professional. Always consult your doctor or pharmacist before starting, stopping, or changing the dosage of Ponaxen 15 Mg (Ponatinib). If you are taking this medication, you should follow strict medical instructions.
Reviews
There are no reviews yet.